A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: Extensive follow-up studies (up to 10 years)

American Journal of Tropical Medicine and Hygiene

Volumn 57, Issue 6, 1997, Pages 651-655

  Oliveira Neto, M P ^a   Schubach, A ^a   Mattos, M ^a   Goncalves Costa, S C ^b   Pirmez, C ^b  

^a Funda??o Oswaldo Cruz   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; MEGLUMINE ANTIMONATE;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; DISEASE TRANSMISSION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; LEISHMANIA BRAZILIENSIS; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRURITUS; SKIN LEISHMANIASIS;

EID: 0031461177     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1997.57.651     Document Type: Article

References (33)

1. WHO, 1984. The Leishmaniasis. World Health Organ Tech Rep Ser 701: 1-140.
2. Herwaldt BL, Herman JD, 1992. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 46: 296-306.
3. Koff AB, Rosen T, 1995. Treatment of cutaneous leishmaniasis. J Am Acad Dermatol 31: 693-708.
4. Berman JD, 1989. The future for antileishmanial chemotherapeutic agents: a review. Hart DT, ed. Leishmaniasis. The Current Status and New Strategies for Control. New York: Plenum Press, 699-704.
5. Grimaldi G, Tesh RB, McMahon-Pratt D, 1989. A review of geographic distribution and epidemiology of leishmaniasis in the New World. Am J Trop Med Hyg 41: 687-725.
6. v) in American cutaneous leishmaniasis. A five-year follow-up study of 15 patients. Mem Inst Oswaldo Cruz 91: 207-209.
7. Oliveira MP, Schubach A, Mattos M, Pirmez C, Goncalves-Costa SC, 1997. Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Pathol Biol 45: 496-499.
8. Chulay J, Spencer H, Mugambi M, 1985. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 34: 702-709.
9. Hepburn NC, Siddique I, Howie AF, Beckett GJ, Hayes PC, 1993. Hepatotoxicity of sodium stibogluconate in leishmaniasis. Lancet 343: 238-239.
10. Braconier JH, Miorner H, 1993. Recurrent episodes of thrombocytopenia during treatment with sodium stibogluconate. J Antimicrob Chemother 31: 187-188.
11. Hepburn NC, Nolan J, Fenn L, Herd RM, Neilson JM, Sutherland GR, Fox KA, 1994. Cardiac effects of sodium stibogluconate: myocardial, electrophysiological and biochemical studies. Q J Med 87: 465-472.
12. Barthet M, Brunet P, Bernard JC, Dussol B, Rodor F, Jouglard J, Berland Y, Sahel J, 1994. Acute pancreatitis during treatment with meglumine antimoniate (Glucantime). Gastroenterol Clin Biol 18: 90-92.
13. Cuce LC, Belda W Jr, Dias MC, 1990. Renal changes caused by pentavalent antimonial (Glucantime) hypersensitivity in American tegumentary leishmaniasis. Report of a case. Rev Inst Med Trop Sao Paulo 32: 249-251.
14. Lopes UG, Momen H, Grimaldi G, Marzochi MCA, Pacheco RS, Morel CM, 1984. Schizodeme and zymodeme characterization of Leishmania. The investigation of foci of visceral and cutaneous leishmaniasis. J Parasitol 70: 89-98.
15. Grimaldi G, David JR, McMahon-Pratt D, 1987. Identification and distribution of New World Leishmania species characterized by serodeme analysis using monoclonal antibodies. Am J Trop Med Hyg 36: 270-287.
16. Oster C, Chulay J, Hendricks L, Pamplin CL, Ballou WR, Berman JD, Takafuji ET, Tramont EC, Canfield CJ, 1985. American cutaneous leishmaniasis: a comparison of three sodium stibogluconate treatment schedules. Am J Trop Med Hyg 34: 856-860.
17. Evans TG, 1993. Leishmaniasis. Infect Dis Clin North Am 7: 527-546.
18. Ballou WR, Gordon D, Andujar J, McClain JB, Shanks GD, Berman JD, Chulay JD, 1987. Safety and efficacy of high dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet 2: 13-16.
19. Costa JML, Marsden PD, 1988. Low dose Glucantime therapy in Leishmania (Viannia) braziliensis (Lvb) infections. Rev Soc Bras Med Trop 21: 85-86.
20. Arana BA, Navin TR, Arana FE, Berman JD, Rosenkaimer F, 1994. Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. Clin Infect Dis 18: 381-384.
21. Pearson RD, Wheeler DA, Harrinson LH, Kay HD, 1983. The immunobiology of leishmaniasis. Rev Infect Dis 5: 907-927.
22. Berman JD, 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy and future strategies. Rev Infect Dis 10: 560-586.
23. Marsden PD, 1986. Mucosal leishmaniasis ("Espundia", Escomel, 1911). Trans R Soc Trop Med Hyg 80: 859-876.
24. Cuba-Cuba CA, Evans D, Rosa AC, Marsden PD, 1991. Clonal variation within a mucosal isolate derived from a patient with Leishmania (Viannia) braziliensis infection. Rev Inst Med Trop Sao Paulo 33: 343-350.
25. Saravia NG, Holguin AF, McMahon-Pratt D, D'Alessandro A, 1995. Mucocutaneous leishmaniasis in Colombia: Leishmania braziliensis subspecies diversity. Am J Trop Med Hyg 34: 714-720.
26. Weigle KA, Saravia NG, Davalos M, 1996. Leishmania braziliensis from the Pacific coast region of Colombia: foci of transmission, clinical spectrum and isoenzyme phenotypes. Am J Trop Med Hyg 35: 722-731.
27. Olliaro PL, Bryceson ADM, 1993. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 9: 323-328.
28. Mendonca SCF, Souza W, Nunes M, Marzochi MCA, Coutinho SG, 1988. Indirect immunofluorescence test in New World leishmaniasis: serological and clinical relationship. Mem Inst Oswaldo Cruz 53: 347-355.
29. Murray H, Berman J, Wright S, 1988. Immunochemotherapy for intracellular Leishmania donovani infection: gamma-interferon plus pentavalent antimony. J Infect Dis 157: 973-978.
30. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceicao-Silva F, Modlin RL, 1993. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 91: 1390-1395.
31. Marsden P, Llanos-Cuentas E, Lago E. Cuba CAC, Barreto AC, Costa JM, Jones TC, 1984. Human mucocutaneous leishmaniasis in Tres Bracos, Bahia, Brazil. Am area of Leishmania braziliensis braziliensis transmission. III. Mucosal disease presentation and initial evolution. Rev Soc Braz Med Trop 17: 179-186.
32. Jones TC, Johnson WD, Barreto AC, 1987. Epidemiology of cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis 156: 73-83.
33. Llanos-Cuentas EA, Cuba CC, Barreto AC, Marsden PD, 1984. Clinical characteristics of human Leishmania braziliensis braziliensis infections. Trans R Soc Trop Med Hyg 78: 845-846.